1.10Open1.10Pre Close0 Volume41 Open Interest310.00Strike Price0.00Turnover96.24%IV32.79%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier12DDays to Expiry1.10Extrinsic Value100Contract SizeAmericanOptions Type0.0687Delta0.0032Gamma199.39Leverage Ratio-0.2169Theta0.0051Rho13.71Eff Leverage0.0571Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet